RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF MOXIFLOXACIN AND DIFLUPREDNATE IN THEIR COMBINED DOSAGE FORM

  • Mayank Patel Gujarat Technological University

Abstract

Moxifloxacin is synthetic fluoroquinolone antibiotic agent and Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. This combination of drugs will be used to treat optical infections. In RP-HPLC method, a mobile phase of Phosphate Buffer (pH 3.5) : Methanol (35:65 v/v)  was used to resolve Moxifloxacin and Difluprednate from a mixture. The linearity range obtained for the HPLC method were 25 - 75 μg/ml and 2.5 – 7.5 μg/ml with corresponding correlation coefficient of 0.998 and 0.997, for Moxifloxacin and Difluprednate respectively. Flow rate was set to 1 ml/min and detection was carried out at 244 nm. The method was found to be rapid, accurate and precise. This method was validated according to ICH guidlines.

Downloads

Download data is not yet available.

Author Biography

Mayank Patel, Gujarat Technological University
Department of Quality Assurance
Statistics
73 Views | 138 Downloads
How to Cite
Patel, M. (2014). RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF MOXIFLOXACIN AND DIFLUPREDNATE IN THEIR COMBINED DOSAGE FORM. Journal of Drug Delivery and Therapeutics, 4(4), 60-65. https://doi.org/10.22270/jddt.v4i4.913